Roche bags breakthrough status for autism hope balovaptan
Roche has been awarded breakthrough status for a drug that has shown some signs of activity in autism spectrum disorders, according to reports.
Balovaptan (RG7314) aims to treat autism by modulating the activity of vasopressin, a hormone that first emerged as a possible drug target in the disorder a few years ago. It blocks the activity of the V1a vasopressin receptor subtype and is currently in phase 2 testing.
Reuters said this morning that the FDA granted breakthrough status to the program in the hope of accelerating its progress through development and onto the market.
- Read Full Item
- 29th January 2018
- Fierce Biotech